Blog & News
TRC105 in combination with pazopanib vs. pazopanib alone in advanced angiosarcoma (TAPPAS)
This study evaluates the efficacy and safety of TRC105 in combination with pazopanib vs. pazopanib alone in advanced angiosarcomas. Trial name TAPPAS Agents TRC105 and pazopanib Phase III Status Terminated Sponsor Tracon Pharmaceuticals Inc. A randomized phase III trial of TRC105 and…
invictus: DCC-2618 vs. placebo in advanced pre-treated GIST patients
Agents: DCC-2618 vs. placebo Phase III Status Closed, active Sponsor Deciphera Pharmaceuticals LLC Further information: https://clinicaltrials.gov/ct2/show/NCT03353753 WHO is the trial for? Patients with confirmed advanced or metastatic GIST with all types of mutation in KIT or PDGFRa (excluded are…
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas (DOREMY)
Agents: Radiotherapy Phase II Status Closed, active Sponsor The Netherlands Cancer Institute Further information: https://clinicaltrials.gov/ct2/show/NCT02106312 WHO is the trial for? Adult patients with confirmed Myxoid Liposarcoma (MLS) of the soft tissue without metastasis or with only a small number of…
Trabectedin Maintenance
Trabectedin Maintenance post 1st-line in STS Agents: Trabectedin Phase III Status Open, recruiting Sponsor EORTC in collaboration with PharmaMar Further information: https://clinicaltrials.gov/ct/show/NCT02929394 or http://www.eortc.org/research_field/clinical-detail/1447/ Maintenance therapy with Trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or…
ANITA
ANITA – Nintedanib with Ifosfamide in advanced, metastatic Soft Tissue Sarcoma (STS) Agents: Nintedanib vs. Ifosfamide Phase II Status Closed, active Sponsor EORTC in collaboration with Boehringer Ingelheim Further information: https://clinicaltrials.gov/ct/show/NCT02808247 or http://www.eortc.org/research_field/clinical-detail/1506/ A Phase II study comparing Nintedanib…
Navigator: Avapritinib (BLU-285)
NAVIGATOR: Avapritinib (BLU-285) Phase I study of Avapritinib (formerly BLU-285) in patients with GIST and other relapsed/refractory solid tumors (Navigator). Trial name: Navigator Agents: Avapritinib (formerly BLU-285) Phase I Status Completed Sponsor Blueprint Medicines Corporation Further information: https://www.clinicaltrials.gov/ct2/show/NCT02508532?term=NCT02508532&rank=1 WHO is the trial…
Cabozantinib in High Grade Uterine Sarcoma (HGUtS)
Maintenance therapy with Cabozantinib in High Grade Uterine Sarcoma (HGUtS) Agents: Cabozantinib Phase II Status Open, recruiting Sponsor EORTC Further information: https://clinicaltrials.gov/ct/show/NCT01979393 or http://www.eortc.org/research_field/clinical-detail/62113/ A phase II study evaluating the role of maintenance therapy with Cabozantinib in High Grade Uterine…
Crenolanib in patients with D842V mutated GIST
Randomized trial of Crenolanib in patients with D842V mutated GIST Trial name CrenoGIST Agents: Crenolanib vs. placebo Phase III Status Closed, active Sponsor Arog Pharmaceuticals, Inc. Further information: https://clinicaltrials.gov/ct2/show/NCT02847429?term=crenolanib+Gist&rank=2 WHO is the trial for? Patients with confirmed advanced or metastatic GIST…
Euro Ewing 2012
Trial for the Treatment of Newly Diagnosed Ewing’s Sarcoma Family of Tumours Agents: Different chemotherapy regimens Phase III Status Open, recruiting Sponsor University of Birmingham Further information: https://www.ucl.ac.uk/cancer/research/centres-and-networks/euro-ewing-consortium/clinical-trials/euro-ewing-2012/ee2012 WHO is the trial for? Patients with diagnosed Ewing’s sarcoma, primitive…
ALT GIST
ALT GIST The ALT-GIST compares imatinib with an alternating regime of imatinib and regorafenib in patients with confirmed, metastatic GIST without previous therapy. The trial is currently open for participation in several countries. Agents: Imatinib alternating with Regorafenib vs. Imatinib alone Phase…